Health sciences

COVID-19: AHF Warns Biden Administration, ‘You Are Courting Disaster on Global Vaccines’

Thursday, April 15, 2021 - 10:24pm

b'AIDS Healthcare Foundation ( AHF ) today called on U.S. President Joseph R. Biden to support the temporary waiver of patent rights for COVID-19 vaccines as currently proposed at the World Trade Organization (WTO).

Key Points: 
  • b'AIDS Healthcare Foundation ( AHF ) today called on U.S. President Joseph R. Biden to support the temporary waiver of patent rights for COVID-19 vaccines as currently proposed at the World Trade Organization (WTO).
  • Lethal mutations and variants of this deadly virus will take hold and spread like wildfire across the globe to unvaccinated populations.
  • Granting the waiver will accelerate vaccine production and distribution.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415006084/en/\n'

Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders

Thursday, April 15, 2021 - 9:10pm

Gene editing is an investigational technique that is used to add, delete, or correct a patient\xe2\x80\x99s genetic material in an effort to treat a disease.

Key Points: 
  • Gene editing is an investigational technique that is used to add, delete, or correct a patient\xe2\x80\x99s genetic material in an effort to treat a disease.
  • Research suggests that editing genes in patients could potentially result in cures for a number of genetic diseases.
  • In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit.
  • These forward-looking statements are not statements of historical fact and relate to the potential completion and execution of a license agreement as described in the press release.

My Intelligent Machines Inc. Secures $5 Million in Seed Financing to Support International Sales and Growing Capabilities

Thursday, April 15, 2021 - 4:14pm

b"My Intelligent Machines Inc. (\xe2\x80\x9cMIMs\xe2\x80\x9d), a leader in artificial intelligence and systems biology, today announced that it has completed an equity financing of $5 million.

Key Points: 
  • b"My Intelligent Machines Inc. (\xe2\x80\x9cMIMs\xe2\x80\x9d), a leader in artificial intelligence and systems biology, today announced that it has completed an equity financing of $5 million.
  • We can provide a better understanding of patient heterogeneity with respect to both disease and response to treatment.
  • Our platform enables the identification of targets for drugs with increased efficacy, prioritization of indications at pre-clinical stages and reduction of clinical trial failure rate,\xe2\x80\x9d said Sarah Jenna, Ph.D., co-founder and CEO of My Intelligent Machines.
  • In late 2020, MIMs received the Red Herring\xe2\x80\x99s Top 100 North America Award, one of the most prestigious prizes granted each year to the most promising private tech companies.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005755/en/\n"

Aspen Dental Opens 24th Practice in North Carolina

Thursday, April 15, 2021 - 3:56pm

b'Aspen Dental has officially opened its doors in Wake Forest, North Carolina with the opening of a brand-new office, bringing a renowned dentist to the community.

Key Points: 
  • b'Aspen Dental has officially opened its doors in Wake Forest, North Carolina with the opening of a brand-new office, bringing a renowned dentist to the community.
  • This is the 24th Aspen Dental practice in the state of North Carolina, as Aspen Dental continues to break down barriers and bring comprehensive, affordable care to patients across the country.\nLocated at 12612 Capital Blvd, the office is led by Dr. Mohammad Spouh, who received his DDS degree from Indiana University.
  • Aspen Dental practices are committed to keeping prices low so that patients can get the care they need.
  • Every Aspen Dental practice is equipped with an on-site denture laboratory, which helps facilitate quick turnaround for denture repairs, relines or adjustments.

China Bevacizumab Market Report 2021-2025 Featuring Roche Pharma (AVASTIN) Qilu Pharmaceutical (Ankeda) & Innovent Biologics (BYVASDA) - ResearchAndMarkets.com

Thursday, April 15, 2021 - 3:02pm

b'The "Investigation Report on the Chinese Bevacizumab Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe sales of Bevacizumab in China will continue to grow due to market expansion.

Key Points: 
  • b'The "Investigation Report on the Chinese Bevacizumab Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe sales of Bevacizumab in China will continue to grow due to market expansion.
  • After the medical insurance negotiations in 2017, the price of AVASTIN decreased from CNY5176 to CNY1998.
  • AVASTIN, the original research drug (developed by Roche Pharma), was approved in China in 2010.
  • In addition to Roche Pharma, Qilu Pharmaceutical and Innovent Biologics are the other two manufacturers in the Chinese market.\nUntil June 2020, six companies have submitted go-public applications for Bevacizumab.

Worldwide Topical Pain Relief Industry to 2025 - by Therapeutic Class, Mode of Purchase and Region - ResearchAndMarkets.com

Thursday, April 15, 2021 - 1:15pm

b'Analyses of the global market trends, with data from 2019 and 2020, and projections of compound annual growth rates (CAGRs) through 2025\nExamination of the competitive environment, regulatory scenario and technological advancements which are influencing the growth of generic drugs market\nProfiles of the leading market players, including GlaxoSmithKline, Sanofi S.A., Johnson & Johnson, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.\nGrowth of the global market is attributed to factors such as the growing prevalence of cancer, diabetes and other chronic diseases; and strong investment in research and development activities by key market players including GlaxoSmithKline, SanofiS.A., Johnson& Johnson, SunPharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd., among others.\nThe increasing incidence of acute and chronic pain and rising geriatric populations with osteoporosis-related issues are the major factors likely to fuel the market for topical pain management drugs.\nAccording to the Global Burden of Disease Study 2016, the high prominence of pain and pain-related diseases is the leading cause of disability and disease burden globally.

Key Points: 
  • b'Analyses of the global market trends, with data from 2019 and 2020, and projections of compound annual growth rates (CAGRs) through 2025\nExamination of the competitive environment, regulatory scenario and technological advancements which are influencing the growth of generic drugs market\nProfiles of the leading market players, including GlaxoSmithKline, Sanofi S.A., Johnson & Johnson, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.\nGrowth of the global market is attributed to factors such as the growing prevalence of cancer, diabetes and other chronic diseases; and strong investment in research and development activities by key market players including GlaxoSmithKline, SanofiS.A., Johnson& Johnson, SunPharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd., among others.\nThe increasing incidence of acute and chronic pain and rising geriatric populations with osteoporosis-related issues are the major factors likely to fuel the market for topical pain management drugs.\nAccording to the Global Burden of Disease Study 2016, the high prominence of pain and pain-related diseases is the leading cause of disability and disease burden globally.
  • In 2016, the burden of chronic pain increased, with 1.9 billion people with symptomatic chronic conditions.
  • The burden of chronic pain is likely to drive the market for topical pain management drugs during the forecast period.\nThe global topical pain management drugs market is segmented based on therapeutic class, mode of purchase and region.\n'

Medable Secures Another $78 Million Funding to Fuel Digital Innovation for Patient-Centered Drug Development

Thursday, April 15, 2021 - 12:37pm

b'Medable Inc. today announced $78 million in new funding to fuel advances in the delivery of digital and decentralized clinical trials, accelerating the industry\xe2\x80\x99s shift to patient-centered drug development.

Key Points: 
  • b'Medable Inc. today announced $78 million in new funding to fuel advances in the delivery of digital and decentralized clinical trials, accelerating the industry\xe2\x80\x99s shift to patient-centered drug development.
  • Medable will use the funding to continue enabling broad adoption of digital trials and patient-centric strategies at global scale.
  • By minimizing the need for in-person site visits, Medable customers have achieved unprecedented results \xe2\x80\x93 including 3X faster enrollment and over 90 percent retention rates.
  • \xe2\x80\x9cMedable is committed to delivering the leading solutions to drug developers for this incredibly important change in how clinical research is conducted.

Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer

Thursday, April 15, 2021 - 1:00pm

b'Tallac Therapeutics, Inc. (\xe2\x80\x9cTallac\xe2\x80\x9d), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Curtis Hecht as Chief Business Officer\n\xe2\x80\x9cWe are delighted to welcome Curtis to Tallac.

Key Points: 
  • b'Tallac Therapeutics, Inc. (\xe2\x80\x9cTallac\xe2\x80\x9d), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Curtis Hecht as Chief Business Officer\n\xe2\x80\x9cWe are delighted to welcome Curtis to Tallac.
  • Curtis\xe2\x80\x99s extensive industry experience spearheading research and development collaborations and partnerships will be invaluable to Tallac as we advance multiple assets from our novel TRAAC platform,\xe2\x80\x9d said Hong I. Wan, Ph.D., President, Chief Executive Officer and co-founder of Tallac.\nCurtis Hecht joins the company with over 25 years of leadership, corporate strategy and business development experience, most recently from Calithera Biosciences, Inc. where he served as Chief Business Officer.
  • Previously, Curtis held senior business development roles at various life sciences and biotechnology companies including DNA Ink, inVentiv Health, Genentech and Roche.
  • \xe2\x80\x9cI\xe2\x80\x99m excited at the opportunity to work with the exceptional team at Tallac during this pivotal phase of its growth.\xe2\x80\x9d\nTallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer.

Aceto Strengthens Self-Manufacturing and Vaccine and Biopharmaceutical Offering With Acquisition of A&C

Thursday, April 15, 2021 - 2:30pm

With A&C, Aceto now provides customers greater access to critical raw materials and excipients used in synthesizing biologics, as well as enhanced support throughout the drug development process.\n\xe2\x80\x9cWith the acquisition of A&C, Aceto has materially expanded its self-manufactured and custom product offerings in the vaccine and biopharmaceutical space,\xe2\x80\x9d said Gilles Cottier, Chief Executive Officer of Aceto.

Key Points: 
  • With A&C, Aceto now provides customers greater access to critical raw materials and excipients used in synthesizing biologics, as well as enhanced support throughout the drug development process.\n\xe2\x80\x9cWith the acquisition of A&C, Aceto has materially expanded its self-manufactured and custom product offerings in the vaccine and biopharmaceutical space,\xe2\x80\x9d said Gilles Cottier, Chief Executive Officer of Aceto.
  • With business operations in nine countries, Aceto distributes over 1,100 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural, and specialty chemical industries.
  • www.aceto.com\nA&C is a global GMP manufacturer of excipients, buffers, process solutions and a select number of active pharmaceutical ingredients (APIs).
  • A&C is committed to providing certified GMP products in full compliance with international regulatory requirements to meet customers\xe2\x80\x99 needs globally.\n"

Columbia Care Launches First of Its Kind Medical Cannabis Capsule in UK; Provides More Precise Dosing Option and Longer Lasting Therapeutic Benefits for Physicians and Patients

Thursday, April 15, 2021 - 8:00am

This is the first solid-fill capsule of its kind available in the UK and the first dose-metered medicinal cannabis product to be manufactured in the UK.

Key Points: 
  • This is the first solid-fill capsule of its kind available in the UK and the first dose-metered medicinal cannabis product to be manufactured in the UK.
  • These dosing options enable prescribing physicians to offer proven, cannabis-based medical solutions with a degree of precision previously unavailable in the UK market.
  • We believe this has the potential to truly drive normalization around cannabis use for physicians and patients alike,\xe2\x80\x9d said Rosemary Mazanet, M.D./Ph.D., Chief Scientific Officer, Columbia Care.
  • Not only are most patients familiar with a capsule, but many will also see other benefits of this formulation.